Following the recommendation for regulatory approval under the European decentralized procedure, Toctino received national regulatory approval in Denmark.
The Danish Medicines Agency approved label for Toctino indicates ‘for use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids’.
Marketing applications for the use of Toctino (alitretinoin) in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.